Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process

Cancer Research

Volumn 59, Issue 19, 1999, Pages 5030-5036

  Craft, Noah ^a   Chhor, Chloe ^a   Tran, Chris ^a   Belldegrun, Arie ^a,b   DeKernion, Jean ^a,b   Witte, Owen N ^a,b   Said, Jonathan ^a,b   Reiter, Robert E ^a,b   Sawyers, Charles L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CASTRATION; CONTROLLED STUDY; HORMONE RESPONSE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR GROWTH;

ANDROGENS; ANIMALS; CELL DIVISION; CLONE CELLS; DIHYDROTESTOSTERONE; DRUG IMPLANTS; FEMALE; HUMANS; MALE; MICE; MICE, SCID; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033215472     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Kyprianou, N., and Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122: 552-562, 1988.
2. Kinbara, H., Cunha, G. R., Boutin, E., Hayashi, N., and Kawamura, J. Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Prostate, 29: 107-116, 1996.
3. Cunha, G. R. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer (Phila.), 74: 1030-1044, 1994.
4. Westin, P., Stattin, P., Damber, J. E., and Bergh, A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol., 146: 1368-1375, 1995.
5. Reuter, V. E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology, 49: 16-22, 1997.
6. Murphy, W. M., Soloway, M. S., and Barrows, G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer (Phila.), 68, 821-828, 1991.
7. Talpin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
8. Gaddipati, J. P., McLeod, D. G., Heidenberg, H. B., Sesterhenn, I. A., Finger, M. J., Moul, J. W., and Srivastava, S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res., 54: 2861-2864, 1994.
9. Brinkmann, A. O., Jenster, G., Ris-Stalpers, C., van der Korput, J. A., Bruggenwirth, H. T., Boehmer, A. L., and Trapman, J. Androgen receptor mutations. J. Steroid Biochem. Mol. Biol., 53: 443-448, 1995.
10. Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., and Barrack, E. R. Androgen receptor gene mutations in human prostate cancer Proc. Natl. Acad. Sci. USA, 89: 6319-6323, 1992.
11. Tilley, W. D., Buchanan, G., Hickey, T. E., and Bentel, J. M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res., 2: 277-285, 1996.
12. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M. M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
13. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5: 280-285, 1999.
14. Abreu-Martin, M. T., Chari, A., Palladino, A. A., Craft, N. A., and Sawyers, C. L. Mitogen-activated protein kinase kinase kinase (MEKK1) activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol. Cell. Biol., 19: 5143-5154, 1999.
15. Gioeli, D., Mandell, J, W., Petroni, G. R., Frierson, H. F., Jr., and Weber, M. J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res., 59: 279-284, 1999.
16. Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., and French, F. S. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res., 58: 5718-5724, 1998.
17. Craft, N., and Sawyers, C. L. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev., 17: 421-427, 1999.
18. Liu, A. Y., Corey, E., Bladou, F., Lang, P. H., and Vessella, R. L. Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int. J. Cancer, 65: 85-89, 1996.
19. Reiter, R. E., Magi-Galluzzi, C., Hemmati, H., Sawyers, C. L., Loda, M., and Witte, O. N. Two genes upregulated in androgen-independent prostate cancer are also selectively expressed in the basal cells of normal prostate epithelium. J. Urol., 157: 269A, 1997.
20. Isaacs, J. T., and Coffey, D. S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res., 41: 5070-5075, 1981.
21. Isaacs, J. T. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Cancer Res., 42: 5010-5014, 1982.
22. Isaacs, J. T., Wake, N., Coffey, D. S., and Sandberg, A. A. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res., 42: 2353-2371, 1982.
23. Wake, N., Isaacs, J., and Sandberg, A. A. Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res., 42: 4131-4142, 1982.
24. Gingrich, J. R., Barrios, R. J., Kattan, M. W., Nahm, H. S., Finegold, M. J., and Greenberg, N. M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res., 57: 4687-4691, 1997.
25. Akakura, K., Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., Tenniswood, M., and Fox, K. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (Clusterin) gene in the Shionogi carcinoma. J. Steroid Biochem. Mol. Biol., 59: 501-511, 1996.
26. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., and Lawson, D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 50: 2275-2282, 1990.
27. Rennie, P. S., Bruchovsky, N., and Coldman, A. J. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J. Steroid Biochem. Mol. Biol., 37: 843-847, 1990.
28. Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., and Sawyers, C. L. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med., 3: 402-408, 1997.
29. Luria, S. E., and Delbruck, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics, 28: 491-511, 1943.
30. Marcelli, M., Tilley, W. D., Wilson, C. M., Griffin, J. E., Wilson, J. D., and McPhaul, M. J. Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. Mol. Endocrinol., 90: 1105-1116, 1990.
31. Nagabhushan, M., Miller, C. M., Pretlow, T, P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H-J., deVere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. CRW22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042-3046, 1996.
32. Bladou, F., Vessella, R., Buhler, K. R., Ellis, W. J., True, L. D., and Lange, P. H. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int. J. Cancer, 67: 785-790, 1996.
33. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
34. van Weerden, W. M., van Kreuningen, A., Elissen, N. M., Vermeij, M., de Jong, F. H., van Steenbrugge, G. J., and Schroder, F. H. Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate, 23: 149-164, 1993.
35. Schulze, H., Isaacs, J., and Senge, T. Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. J. Urol., 137: 909-911, 1987.
36. Montironi, R., Pomante, R., Diamanti, L., and Magi-Galluzzi, C. Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol. Int., 60: 25-29, 1998.
37. Gleave, M. E., Goldenberg, S. L., Jones, E. C., Bruchovsky, N., and Sullivan, L. D. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol., 155: 213-219, 1996.
38. Gao, J., and Isaacs, J. T. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res., 58: 3299-3306, 1998.
39. Horoszewicz, J., Leong, S., Kawinski, E., Karr, J., Rosenthal, H., Chu, T., Mirand, E., and Murphy, G. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
40. Wainstein, M. A., He, F., Robinson, D., Kung, H. J., Schwartz, S., Gianconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., Kursh, E. D., Resnick, M. I., Seftel, A., and Pretlow, T. G. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 54: 6049-6052, 1994.
41. Vaux, D. L., Cory, S., and Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (Lond.), 335: 440-442, 1988.
42. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
43. Apakama, I., Robinson, M. C., Walter, N. M., Charlton, R. G., Royds, J. A., Fuller, C. E., Neal, D. E., and Hamdy, F. C. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br. J. Cancer, 74: 1258-1262, 1996.
44. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol., 148: 1567-1576, 1996.
45. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C., and Mihatsch, M. J. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol., 148: 1557-1565, 1996.
46. Stattin, P., Damber, J. E., Karlberg, L., Nordgren, H., and Bergh, A. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol. Res., 24: 257-264, 1996.
47. Watanabe, M., Shiraishi, T., Muneyuki, T., Nagai, M., Fukutome, K., Murata, M., Kawamura, J., and Yatani, R. Allelic loss and microsatellite instability in prostate cancers in Japan. Oncology, 55: 569-574, 1998.
48. Dahiya, R., Lee, C., McCarville, J., Hu, W., Kaur, G., and Deng, G. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int. J. Cancer, 72: 762-767, 1997.
49. Cunningham, J. M., Shan, A., Wick, M. J., McDonnell, S. K., Schaid, D. J., Tester, D. J., Qian, J., Takahashi, S., Jenkins, R. B., and Bostwick, D. G. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res., 56: 4475-4482, 1996.
50. Egawa, S., Uchida, T., Suyama, K., Wang, C., Ohori, M., Irie, S., Iwamura, M., and Koshiba, K. Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables. Cancer Res., 55: 2418-2421, 1995.
51. Gao, X., Wu, N., Grignon, D., Zacharek, A., Liu, H., Salkowski, A., Li, G., Sakr, W., Sarkar, F., Porter, A. T., Chen, Y. Q., and Honn, K. V. High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene, 9: 2999-3003, 1994.
52. Fidler, I. J., and Hart, I. R. Biological diversity in metastatic neoplasms: origins and implications. Science (Washington DC), 217: 998-1003, 1982.
53. Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res., 38: 2651-2660, 1978.
54. Stapleton, A. M. F., Timme, T. L., Gousse, A. E., Li, Q. F., Tobon, A. A., Kattan, M. W., Slawin, K. M., Wheeler, T. M., Scardino, P. T., and Thompson, T. C. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin. Cancer Res., 3: 1389-1397, 1997.